Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
JCI Insight|April 20, 2018
Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine modelBenjamin Y Jin, Tracy E Campbell, Lindsey M Draper, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2015
Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cell-Mediated Tumor Control in the Genital TractYun-Yan Sun, Shiwen Peng, Liping Han, et al.
Gynecologic Oncology|February 2, 2020
A first-in-human proof-of-concept trial of intravaginal artesunate to treat cervical intraepithelial neoplasia 2/3 (CIN2/3)Cornelia L Trimble, Kimberly Levinson, Leonel Maldonado, et al.
Science Translational Medicine|January 31, 2014
Intramuscular therapeutic vaccination targeting HPV16 induces T cell responses that localize in mucosal lesionsLeonel Maldonado, Jessica E Teague, Matthew P Morrow, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 8, 2005
Spontaneous regression of high-grade cervical dysplasia: effects of human papillomavirus type and HLA phenotypeCornelia L Trimble, Steven Piantadosi, Patti Gravitt, et al.
Gynecologic Oncology|December 14, 2011
Karyometry in atypical endometrial hyperplasia: a Gynecologic Oncology Group studyPeter H Bartels, Francisco A R Garcia, Cornelia L Trimble, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2014
Toll-like receptor agonist imiquimod facilitates antigen-specific CD8+ T-cell accumulation in the genital tract leading to tumor control through IFNγRuey-Shyang Soong, Liwen Song, Janson Trieu, et al.
Clinical and Vaccine Immunology : CVI|May 15, 2015
Seroepidemiology of Human Papillomavirus 16 (HPV16) L2 and Generation of L2-Specific Human Chimeric Monoclonal AntibodiesJoshua W Wang, Subhashini Jagu, Wai-Hong Wu, et al.
Gynecologic Oncology|December 1, 2015
A pilot study of pNGVL4a-CRT/E7(detox) for the treatment of patients with HPV16+ cervical intraepithelial neoplasia 2/3 (CIN2/3)Ronald D Alvarez, Warner K Huh, Sejong Bae, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2017
Clinical and Immunologic Biomarkers for Histologic Regression of High-Grade Cervical Dysplasia and Clearance of HPV16 and HPV18 after ImmunotherapyMatthew P Morrow, Kimberly A Kraynyak, Albert J Sylvester, et al.
Pageof 4